2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176000
    Sulphostin 307345-51-3 98%
    Sulphostin is a covalent inhibitor of dipeptidyl peptidase 4 (DPP4), dipeptidyl peptidase 9 (DPP9), and dipeptidyl peptidase 8 (DPP8) with IC50 values of 79, 1392, 6930 nM, respectively. Sulphostin causes phosphosulfamate modification, irreversibly inhibits the enzyme activity. Sulphostin can be used for inflammation and cancer study.
    Sulphostin
  • HY-176001
    DPP8/9-IN-1 98%
    DPP8/9-IN-1 (Compound 16) is a selective covalent inhibitor of dipeptidyl peptidases 8 and 9 (DPP8/9) with IC50 values of 14 and 298 nM, respectively. DPP8/9-IN-1 binds irreversibly to the active site serine (S730 in DPP9) via a phosphonate warhead and blocks substrate binding to inhibit DPP8/9-mediated protein processing. DPP8/9-IN-1 is promising for research of cancers and inflammatory diseases.
    DPP8/9-IN-1
  • HY-176028
    N-Stearoyl-DPPE ammonium 98%
    N-Stearoyl-DPPE ammonium is a type of N-acylphosphatidylethanolamine (NAPE). N-Stearoyl-DPPE ammonium is an important intermediate in the endocannabinoid biosynthesis pathway.
    N-Stearoyl-DPPE ammonium
  • HY-176057
    S118 2677041-36-8 98%
    S118 is an orally active sphingosine-1-phosphate receptor 2 (S1P2 receptor) inhibitor. S118 prevents the binding of the S1P2 receptor to dapper1 (Dpr1), reduces the accumulation of β-catenin and blocks the nuclear translocation of the S1P2 receptor, thereby inhibiting inflammation, fibrosis, and epithelial-mesenchymal transition (EMT) and exerting anti-idiopathic pulmonary fibrosis (IPF) activity. S118 is promising for research of idiopathic pulmonary fibrosis.
    S118
  • HY-176126
    STING agonist-42 2942231-48-1 98%
    STING agonist-42 (compound 8a) is a potent STING agonist. STING agonist-42 activates STING in THP1 and RAW 264.7 cells with EC50s of 0.06 and 14.15 μM, respectively.
    STING agonist-42
  • HY-176131
    AMX5160 2639293-95-9 98%
    AMX5160 (36) is an orally active BTK inhibitor, with an IC50 of 0.98 nM against mutant BTKC481S. AMX5160 (36) can be used in the research for leukemia, lymphoma, multiple sclerosis, and other autoimmune diseases.
    AMX5160
  • HY-176133
    ROCK-IN-12 98%
    ROCK-IN-12 (compound R3) is a selective ROCK inhibitor. ROCK-IN-12 can be used in the study of glaucoma.
    ROCK-IN-12
  • HY-176139
    URAT1 inhibitor 13 2816864-54-5 98%
    URAT1 inhibitor 13 (compound 22k) is a potent URAT1 inhibitor. URAT1 inhibitor 13 can be used in the study of gout .
    URAT1 inhibitor 13
  • HY-176143
    P2Y1/P2Y6 antagonist 1 98%
    P2Y1/P2Y6 antagonist 1 (Compound 3h) is an indolesulfonylhydrazide derivative. P2Y1/P2Y6 antagonist 1 is an orally active tP2Y1 and rP2Y6 antagonist (IC50 of 9.72 and 1.89 μM, respectively). P2Y1/P2Y6 antagonist 1 can be used in the study of neurological diseases, inflammation, cardiovascular diseases and cancer.
    P2Y1/P2Y6 antagonist 1
  • HY-176146
    Keap1/Nrf2/ARE activator 1 98%
    Keap1/Nrf2/ARE activator 1 (compound HT-3) is a Keap1/Nrf2/ARE pathway activator. Keap1/Nrf2/ARE activator 1 exhibits antioxidant activity and neuroprotective efficacy.
    Keap1/Nrf2/ARE activator 1
  • HY-176181
    Thalidomide-4-PEG4-OTs 3023389-80-9 98%
    Thalidomide-4-OH-PEG4-OTs is an E3 ligase ligand-linker conjugate that incorporates the Thalidomide (HY-14658) based CRBN ligand (HY-103596) and 4-unit PEG linker (HY-176182). Thalidomide-4-OH-PEG4-OTs can be used for synthesis of PROTAC STING degrader-4 (HY-176180).
    Thalidomide-4-PEG4-OTs
  • HY-176182
    Br-C2-PEG3-OTs 2757925-36-1 98%
    Br-C2-PEG3-OTs is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs, such as PROTAC STING degrader-4 (HY-176180).
    Br-C2-PEG3-OTs
  • HY-176183
    STING ligand-4
    STING ligand-4 (Compound 2) is a nitro-free covalent STING inhibitor with an IC50 < 0.2 μM. STING ligand-4 can be used for synthesis of PROTAC STING degrader-4 (HY-176180).
    STING ligand-4
  • HY-17618A
    Rac-Pemafibrate 848258-31-1 98%
    Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates PPARα activity, with EC50s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.
    Rac-Pemafibrate
  • HY-176194
    Antifibrotic agent 1 98%
    Antifibrotic agent 1 is an orally active anti-idiopathic pulmonary fibrosis (IPF) agent. Antifibrotic agent 1 effectively attenuates IPF-related processes, including TGF-β induced EMT and FMT processes, as well as pro-fibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α and Src family kinases (SFKs), while sparing VEGFRs, FGFRs and Abl to minimize off-target toxicity. Antifibrotic agent 1 has potent anti-fibrotic activity in Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis mice model.
    Antifibrotic agent 1
  • HY-176212
    Ferroptosis-IN-20 98%
    Ferroptosis-IN-20 (Compound 34a) is a Ferroptosis inhibitor (EC50: 24.2 nM) targeting voltage-dependent anion channel (VDAC). Ferroptosis-IN-20 inhibits VDAC oligomerization and lipid peroxidation. Ferroptosis-IN-20 reduces content of ROS, attenuates TFR1-mediated iron uptake, inhibits Fe2+ level and restores glutathione (GSH) level. Ferroptosis-IN-20 alleviates Folic acid (HY-16637)-induced acute kidney injury (AKI).
    Ferroptosis-IN-20
  • HY-176218
    TTTE
    TTTE is a sulfone bischalcone derivative. TTTE has major anti-necrotic, anti-inflammatory and anti-fibrotic activities. TTTE exerts regulatory effects by downregulating key molecules such as Caspase-3, TNF-α, NF-κB and TGF-β. TTTE can be used in the study of liver injury.
    TTTE
  • HY-176234
    PDE4-IN-28 98%
    PDE4-IN-28 (Compound G1) is a PDE4D inhibitor (IC50: 29 nM). PDE4-IN-28 inhibits the production of TNF-α and NO (IC50: 13.32 and 2.32 μM, respectively). PDE4-IN-28 exhibits anti-inflammatory, antibacterial and analgesic effects in a rat pressure ulcer (PU) model and promotes HUVEC cell migration, thereby accelerating wound healing.
    PDE4-IN-28
  • HY-176243
    15-Deoxy-Δ12,14-Prostaglandin J2-2-glyceryl ester 1947405-90-4
    15-Deoxy-Δ12,14-Prostaglandin J2-2-glyceryl ester is a derivate of 15-Deoxy-Δ-12,14-prostaglandin J2 (HY-108568). 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM.
    15-Deoxy-Δ12,14-Prostaglandin J2-2-glyceryl ester
  • HY-176248
    Dimephosphon 14394-26-4
    Dimephosphon is an anti-inflammatory agent with antihistamine and antiserotonin activities. Dimephosphon helps maintain the conduction function of the spinal cord and reduces the excitability of spinal motor neurons in the area surrounding the lesion. Dimephosphon directly activates lymphatic vessel movement and improves lymphatic circulation. Dimephosphon can be used for the study of inflammatory edema, acute spinal cord injury and lymphatic circulation disorders.
    Dimephosphon
Cat. No. Product Name / Synonyms Application Reactivity